Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt
1. SLP forecasts third-quarter sales of $19-$20 million, below estimates. 2. 2025 sales outlook cut to $76-$80 million from $90-$93 million. 3. Market volatility is impacting demand and causing project delays. 4. Company plans workforce reduction of about 10% to enhance efficiency. 5. Stock price fell 23.2% following the announcements and guidance cuts.